Strong differences in the in vitro cytotoxicity of three isomeric dichlorobis(2-phenylazopyridine)ruthenium(II) complexes

Inorganic Chemistry

Volumn 39, Issue 14, 2000, Pages 2966-2967

  Velders, Aldrik H ^a   Kooijman, Huub ^b   Spek, Anthony L ^b   Haasnoot, Jaap G ^a   De Vos, Dick ^c   Reedijk, Jan ^a  

^a LEIDEN UNIVERSITY   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c TEVA Pharmachemie   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CISPLATIN; FLUOROURACIL; PYRIDINE DERIVATIVE; RUTHENIUM COMPLEX; RUTHENIUM DERIVATIVE;

ARTICLE; CANCER CELL CULTURE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CYTOTOXICITY; CYTOTOXICITY TEST; DRUG ACTIVITY; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG SCREENING; DRUG STRUCTURE; HUMAN; HUMAN CELL; ISOMERISM;

ANTINEOPLASTIC AGENTS; ISOMERISM; MODELS, MOLECULAR; MOLECULAR STRUCTURE; RUTHENIUM COMPOUNDS; SUPPORT, NON-U.S. GOV'T;

EID: 0034631675     PISSN: 00201669     EISSN: None     Source Type: Journal    
DOI: 10.1021/ic000167t     Document Type: Article

References (28)

1. Rosenberg, B.; Van Camp, L.; Trosko, J. E.; Mansour, V. H. Nature 1969, 222, 385.
2. Lippert, B. Cisplatin. Chemistry and Biochemistry of a Leading Anticancer Drug; Verlag Helvetica Chimica Acta, Zurich; Wiley-VCH: Weinheim, 1999.
3. Reedijk, J. Chem. Commun. 1996, 801.
4. Clarke, M. J.; Zhu, F.; Frasca, D. R. Chem. Rev. 1999, 99, 2511.
5. Guo, Z.; Sadler, P. J. Angew. Chem., Int. Ed. Engl. 1999, 38, 1512.
6. Keppler, B. K. Metal complexes in cancer chemotherapy; VCH: Weinheim, Germany, 1993.
7. Depenbrock, H.; Schmelcher, S.; Peter, R.; Keppler, B. K.; Weirich, G.; Block, T.; Rastetter, J.; Hanauske, A. R. Eur. J. Cancer 1997, 33, 2404.
8. Sava, G. Ruthenium Compounds in Cancer Chemotherapy; Fricher, S. P., Ed.; Chapman & Hall: London, U.K., 1994.
9. Sava, G.; Alessio, E.; Bergamo, A.; Mestroni, G. Metallopharm. Top. Biol. Inorg. Chem. 1999, 1, 1.
10. Velders, A. H.; Ugozzoli, F.; Biagini-Cingi, M.; Manotti-Lanfredi, A. M.; Haasnoot, J. G.; Reedijk, J. Eur. J. Inorg. Chem. 1999, 213.
11. Velders, A. H.; Pazderski, L.; Ugozzoli, F.; Biagini-Cingi, M.; Manotti-Lanfredi, A. M.; Haasnoot, J. G.; Reedijk, J. Inorg. Chim. Acta 1998, 273, 259.
12. Hartmann, M.; Einhauser, T. J.; Keppler, B. K. Chem. Commun. 1996, 1741.
13. Krause, R. A.; Krause, K. Inorg. Chem. 1980, 19, 2600.
14. Goswami, S.; Chakravarty, A. R.; Chakravorty, A. Inorg. Chem. 1981, 20, 2246.
15. Bao, T.; Krause, K.; Krause, R. A. Inorg. Chem. 1988, 27, 759.
16. Seal, A.; Ray, S. Acta Crystallogr. 1984, C40, 932.
17. -3.
18. Misra, T. K.; Das, D.; Sinha, C.; Ghosh, P.; Pal, C. K. Inorg. Chem. 1998, 37, 1672.
19. Velders, A. H. Manuscript in preparation.
20. 1H NMR.
21. 2] complexes was tested in vitro applying seven well-characterized human tumor-cell lines (MCF-7 (breast cancer), EVSA-T (breast cancer), WIDR (colon cancer), IGROV (ovarian cancer), M19 MEL (melanoma), A498 (renal cancer), and H226 (nonsmall cell lung cancer)) using the microculture sulforhodamine B test (SRB) for the estimation of the cell viability (available in Supporting Information). On suggestion of a referee, the cytotoxicity values are also given in molar concentration, which is more appropriate for a comparison of compounds with different molecular weights.
22. Hotze, A. C. G.; Velders, A. H.; Ugozzoli, F.; Biagini-Cingi, M.; Manotti-Lanfredi, A. M.; Haasnoot, J. G.; Reedijk, J. Inorg. Chem., in press.
23. Nováková, O.; Kaspárková, J.; Vrána, O.; van Vliet, P. M.; Reedijk, J.; Brabec, V. Biochemists 1995, 34, 12369.
24. Van Vliet, P. M.; Haasnoot, J. G.; Reedijkm J. Inorg. Chem. 1994, 33, 1934.
25. Grover, N.; Gupta, N.; Thorp, H. H. J. Am. Chem. Soc. 1992, 114, 3390.
26. Grover, N.; Welch, T. W.; Fairley, T. A.; Cory, M.; Thorp, H. H. Inorg. Chem. 1994, 33, 3544.
27. Velders, A. H.; Hotze, A. C. G.; Haasnoot, J. G.; Reedijk, J. Inorg. Chem. 1999, 38, 2762.
28. Quiroga, A. G. Manuscript in preparation.